Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
A phase 3 trial of Daraxonrasib in pancreatic ductal adenocarcinoma, run by Revolution Medicines, Inc., now recruiting.
Overview
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) is a phase 3 interventional study registered as NCT07252232 by Revolution Medicines, Inc., with 500 participants planned, started 2025-12-15 and due to reach its primary completion in 2029-05-10. Interventions recorded: daraxonrasib. Conditions listed: Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Shares Revolution Medicines, Daraxonrasib, Pancreatic ductal adenocarcinoma.
- TrialStudy of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Shares Revolution Medicines, Daraxonrasib, Pancreatic ductal adenocarcinoma.
- TrialStudy of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut
Shares Revolution Medicines, Daraxonrasib, Pancreatic ductal adenocarcinoma.
- TrialStudy of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Shares Revolution Medicines, Daraxonrasib, Pancreatic ductal adenocarcinoma.
- TrialStudy of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Shares Revolution Medicines, Daraxonrasib.
- TrialStudy of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Shares Revolution Medicines, Daraxonrasib, Pancreatic ductal adenocarcinoma.
- PairingG12D-selective + pan-RAS(ON) inhibitor (zoldonrasib + daraxonrasib)
- TrialStudy of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Shares Revolution Medicines, Daraxonrasib.